search
Back to results

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project (ARON)

Primary Purpose

Infection

Status
Recruiting
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
diagnostic algorithm
Sponsored by
KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Infection focused on measuring antibiotic prescription, infections, decision tree, point-of-care C-reactive protein test, safetynet advice

Eligibility Criteria

6 Months - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria for practices:

  • Being able to recruit acutely ill children (ideally consecutively)
  • Agree to the terms of the clinical study agreement.

Exclusion Criteria for practices:

  • Currently using a POC CRP device as part of their routine care
  • No practices will be excluded on other grounds than the above. Age, demographics, geographic region will not be used to exclude eligible practices. This will provide us with a real-life, representative subset of ambulatory care physicians.

Inclusion criteria for children

  • Children aged 6 months to 12 years, provided informed consent can be obtained
  • presenting with an acute illness episode that started maximum 10 days before the index consultation

Exclusion criteria for children

  • Children who were previously included in this trial
  • children with an underlying known chronic condition (e.g. asthma, immune deficiency)
  • clinically unstable warranting immediate care
  • immunosuppressant medication taken in the previous 30 days
  • trauma as the main presenting problem
  • antibiotics taken in the previous 7 days
  • Unwillingness or inability to provide informed consent

Sites / Locations

  • GPs associated with KU LeuvenRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Intervention: Diagnostic algorithm

Usual care

Arm Description

diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice

In the control arm, patients will receive 'usual care' left at the discretion of the treating physician. Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools. They are expected (but not forced) to follow the Belgian guidelines (as described in "BAPCOC National guidelines and the RIZIV consensus meeting "Rational use of antibiotics in children").

Outcomes

Primary Outcome Measures

antibiotic prescribing rate at index consultation (immediate or delayed)
The primary outcome is the proportion of subjects who were prescribed antibiotic treatment (both immediate and delayed) at the index consultation as recorded by the treating physician.

Secondary Outcome Measures

Clinical recovery during follow-up
the duration (in days) until reaching full clinical recovery
Additional investigations at index consultation and/or during follow-up
- the proportion of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0) and/or during follow-up (day 1 to day 30)
Re-consultation during follow-up
- the proportion of subjects who re-consulted their physician during follow-up (day 1 to day 30)
Antibiotic prescribing rate during follow-up
- the proportion of subjects who were prescribed antibiotic treatment during follow-up (day 1 to day 30)

Full Information

First Posted
July 2, 2020
Last Updated
September 28, 2023
Sponsor
KU Leuven
Collaborators
Universitaire Ziekenhuizen KU Leuven, University Ghent, Universiteit Antwerpen, University of Liege, Vrije Universiteit Brussel, Université Catholique de Louvain
search

1. Study Identification

Unique Protocol Identification Number
NCT04470518
Brief Title
Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project
Acronym
ARON
Official Title
Impact of a Diagnostic Algorithm on Antibiotic Prescribing Rate and Further Management of Acutely Ill Children Presenting to Ambulatory Care: Multicentre, Cluster-randomized, Parallel Group Pragmatic Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 6, 2021 (Actual)
Primary Completion Date
March 1, 2024 (Anticipated)
Study Completion Date
August 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
KU Leuven
Collaborators
Universitaire Ziekenhuizen KU Leuven, University Ghent, Universiteit Antwerpen, University of Liege, Vrije Universiteit Brussel, Université Catholique de Louvain

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Impact of clinical guidance & point-of-care CRP test in children: the ARON project Trial Design: multicentre, cluster-randomized, parallel group pragmatic trial Trial Participants and setting: Children aged 6 months to 12 years of age with an acute illness episode presenting to in-hours general practice or out-of-hospital community paediatrics offices Intervention(s) Diagnostic algorithm: Clinical decision tree: clinician's gut feeling something is wrong, dyspnea, temperature ≥40ºC YES to any : point-of-care CRP ≥5mg/L: additional testing or refer to secondary care <5mg/L: safety netting*, only prescribe antibiotics if advised (guidelines) NO to all : are AB considered? YES : point-of-care CRP ≥5mg/L: safety netting*, only prescribe antibiotics if advised (guidelines) <5mg/L: safety netting*, do not prescribe antibiotics NO: safety netting *safety netting advice: inform parents on what to expect and what to look out for interactive parent information booklet based on previous research Control: Diagnosis and Treatment/Management as per usual care: - guidance on AB prescribing: o Belgische Commissie voor de Coördinatie van het Antibioticabeleid (BAPCOC) guide (updated November 2019) o RIZIV consensus meeting report "Antibiotics in children in ambulatory care" Primary Endpoint: Antibiotic prescribing rate at index consultation Secondary Endpoint(s) - time until full clinical recovery (during follow up (day 1 to day 30)) - additional investigations (at index consultation and/or during follow up (day 1 to day 30)) - re-consultation (during follow up (day 1 to day 30)) - antibiotic prescribing rate (during follow up (day 1 to day 30)) Exploratory endpoints at the index consultation: additional investigations (X-Ray, blood tests, urine tests, etc.) During a follow-up period (day 1 to day 30): - referral to hospital - additional investigations (X-Ray, blood tests, urine tests, etc.) patients with full clinical recovery at day 7 and day 30 admission to hospital mortality cost-effectiveness patient satisfaction qualitative study: endpoints Planned Sample Size: 7000 Timing of the intervention: Intervention at index consultation (at presentation to primary care) Follow-up duration: 30 days follow-up Duration of the trial (FPI-CSR): 43 months
Detailed Description
The investigators aim to strengthen the assessment of acutely ill children in primary care, by introducing a diagnostic algorithm that can decrease antibiotic prescribing. In light of the prior evidence and its results so far, the ARON trial will test the impact of a diagnostic algorithm including a standardised clinical assessment, a POC CRP test, and safety netting advice. Therefore, the investigators propose to assess the clinical and cost-effectiveness of a diagnostic algorithm which includes a decision tree, POC CRP and safety netting advice in acutely ill children aged 6 months to 12 years of age presenting to ambulatory care, on AB prescribing, referral/admission to hospital, additional testing, mortality, and patient satisfaction. More specifically, the investigators' research question is whether this diagnostic algorithm is able to safely reduce antibiotic prescribing in acutely ill children presenting to ambulatory care. The decision whether or not to conduct a POC CRP test will depend on the standardized clinical assessment, i.e. a validated clinical decision tree, and subsequently for low-risk children on the intention to prescribe AB. The investigators will provide clear evidence-based guidance on how to interpret the CRP test result as outlined below. A process evaluation will examine how clinicians use CRP testing in their practice and how parents experience these consultations. The investigators propose a study, where children (6 months to 12 years of age) will be randomised to (a) a diagnostic algorithm with CRP testing and specific guidance on when to prescribe AB or (b) usual care. CRP testing will be done using a finger prick test (result within 4 minutes). The CRP level will then be given to the clinician who will communicate the result to the child/parents. The investigators aim to recruit 7000 children and will collect data registered by the participating physician, from the child's health record and children/parents directly. The investigators will describe how the intervention has worked in practice and how clinicians/parents have experienced these consultations. Guidance will be part of a diagnostic algorithm which includes clinically guided POC CRP testing and safety netting advice to inform parents on what to expect and what to look out for. Individual interviews will be conducted with clinicians and parents taking part in the trial within 30 days after the first contact consultation, to explore the social processes influencing embedding of the intervention within practice, and behaviour change techniques. These individual telephone interviews will be performed with a selection of parents to address whether their concerns were discussed appropriately and whether their expectations were met and how they experienced the consultation and/or POC CRP testing. The safety-netting advice will be supported by a parent information booklet, based on previous research (the "When should I worry"-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the "Mijn kind heeft koorts" booklet (Eefje de Bont, www.thuisarts.nl), and the "Caring for children with coughs"-leaflet (information about how to look after a child who has a cough and when to see the doctor)). The findings of this study could change the practice of ambulatory care physicians and might be of great interest to parents and childcare providers. The investigators will publish the findings of this research in academic journals, present at national conferences and discuss results with groups responsible for the national guidance on how to assess acutely ill children (Domus Medica, SSMG).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection
Keywords
antibiotic prescription, infections, decision tree, point-of-care C-reactive protein test, safetynet advice

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
multicentre, cluster-randomized, parallel group pragmatic trial
Masking
None (Open Label)
Masking Description
Owing to study procedures, children, their parents and physicians will not be masked to the practices' random allocation.
Allocation
Randomized
Enrollment
7000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention: Diagnostic algorithm
Arm Type
Active Comparator
Arm Description
diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice
Arm Title
Usual care
Arm Type
No Intervention
Arm Description
In the control arm, patients will receive 'usual care' left at the discretion of the treating physician. Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools. They are expected (but not forced) to follow the Belgian guidelines (as described in "BAPCOC National guidelines and the RIZIV consensus meeting "Rational use of antibiotics in children").
Intervention Type
Other
Intervention Name(s)
diagnostic algorithm
Intervention Description
Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea). The safety-netting advice will be supported by a parent information booklet, based on previous research (the "When should I worry"-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the "Mijn kind heeft koorts" booklet (Eefje de Bont, www.thuisarts.nl), and the "Caring for children with coughs"-leaflet (information about how to look after a child who has a cough and when to see the doctor)).
Primary Outcome Measure Information:
Title
antibiotic prescribing rate at index consultation (immediate or delayed)
Description
The primary outcome is the proportion of subjects who were prescribed antibiotic treatment (both immediate and delayed) at the index consultation as recorded by the treating physician.
Time Frame
This outcome will be registered immediately at the index consultation (immediately after the intervention)
Secondary Outcome Measure Information:
Title
Clinical recovery during follow-up
Description
the duration (in days) until reaching full clinical recovery
Time Frame
This outcome will be checked from the diary (via app for parents) from first day after the intervention until day of full clinical recovery (up to maximum 30 days after after the intervention)
Title
Additional investigations at index consultation and/or during follow-up
Description
- the proportion of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0) and/or during follow-up (day 1 to day 30)
Time Frame
This composite outcome will be registered immediately after the intervention and/or checked from the patient health record from the first day to day 30 after the intervention
Title
Re-consultation during follow-up
Description
- the proportion of subjects who re-consulted their physician during follow-up (day 1 to day 30)
Time Frame
This outcome will be checked from the patient health record from first day to day 30 after the intervention
Title
Antibiotic prescribing rate during follow-up
Description
- the proportion of subjects who were prescribed antibiotic treatment during follow-up (day 1 to day 30)
Time Frame
This outcome will be checked from the patient health record first day to day 30 after the intervention
Other Pre-specified Outcome Measures:
Title
additional testing at index consultation
Description
the proportion of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0)
Time Frame
immediately after the intervention
Title
additional testing during follow-up
Description
the proportion of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) during follow-up (day 1 to day 30)
Time Frame
during follow-up from first day to day 30 after the intervention
Title
referral to hospital at day 0
Description
the proportion of subjects referred to hospital at index consultation (day 0)
Time Frame
immediately after the intervention
Title
referral to hospital during follow-up
Description
the proportion of subjects referred to hospital during follow-up (day 1 to day 30)
Time Frame
during follow-up from first day to day 30 after the intervention
Title
admission to hospital at day 0
Description
the proportion of subjects admitted to hospital at index consultation (day 0)
Time Frame
immediately after the intervention
Title
admission to hospital during follow-up
Description
the proportion of subjects admitted to hospital during follow-up (day 1 to day 30)
Time Frame
during follow-up from first day to day 30 after the intervention
Title
mortality at day 0
Description
the proportion of subjects who died at index consultation (day 0)
Time Frame
immediately after the intervention
Title
mortality during follow up
Description
the proportion of subjects who died during follow-up (day 1 to day 30)
Time Frame
during follow-up from first day to day 30 after the intervention
Title
clinical recovery at day 7
Description
the proportion of subjects with full clinical recovery at day 7
Time Frame
at day 7 after the intervention
Title
clinical recovery at day 30
Description
the proportion of subjects with full clinical recovery at day 30
Time Frame
at day 30 after the intervention
Title
patient's experience through semi-structured interviews
Description
Patient's experience through semi-structured interviews with pre-defined topic guide
Time Frame
within 7 days after the intervention
Title
Parent's experience through semi-structured interviews
Description
Parent's experience through semi-structured interviews with pre-defined topic guide
Time Frame
within 7 days after the intervention
Title
Physician's experience through semi-structured interviews
Description
Physician's experience through semi-structured interviews with pre-defined topic guide
Time Frame
within 7 days after the intervention
Title
Cost-effectiveness of the intervention
Description
Cost-effectiveness of the intervention: healthcare expenditures in terms of hospitalization, consultations, pharmaceuticals (reimbursed and non-reimbursed), productivity, quality of life
Time Frame
will be assessed retrospectively after data collection has finished (24 months of recruitment)
Title
Adherence to the diagnostic algorithm
Description
proportion of consultation in which the physician did not adhere to the diagnostic algorithm
Time Frame
immediately after the intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria for practices: Being able to recruit acutely ill children (ideally consecutively) Agree to the terms of the clinical study agreement. Exclusion Criteria for practices: Currently using a POC CRP device as part of their routine care No practices will be excluded on other grounds than the above. Age, demographics, geographic region will not be used to exclude eligible practices. This will provide us with a real-life, representative subset of ambulatory care physicians. Inclusion criteria for children Children aged 6 months to 12 years, provided informed consent can be obtained presenting with an acute illness episode that started maximum 10 days before the index consultation Exclusion criteria for children Children who were previously included in this trial children with an underlying known chronic condition (e.g. asthma, immune deficiency) clinically unstable warranting immediate care immunosuppressant medication taken in the previous 30 days trauma as the main presenting problem antibiotics taken in the previous 7 days Unwillingness or inability to provide informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tine De Burghgraeve, PhD
Phone
+3216 37 76 72
Email
tine.deburghgraeve@kuleuven.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Y Verbakel, MD, PhD
Organizational Affiliation
KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
GPs associated with KU Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tine De Burghgraeve

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29269559
Citation
Verbakel JY, Lemiengre MB, De Burghgraeve T, De Sutter A, Aertgeerts B, Bullens DMA, Shinkins B, Van den Bruel A, Buntinx F. Point-of-care C reactive protein to identify serious infection in acutely ill children presenting to hospital: prospective cohort study. Arch Dis Child. 2018 May;103(5):420-426. doi: 10.1136/archdischild-2016-312384. Epub 2017 Dec 21.
Results Reference
background
PubMed Identifier
24025452
Citation
Verbakel JY, Aertgeerts B, Lemiengre M, Sutter AD, Bullens DM, Buntinx F. Analytical accuracy and user-friendliness of the Afinion point-of-care CRP test. J Clin Pathol. 2014 Jan;67(1):83-6. doi: 10.1136/jclinpath-2013-201654. Epub 2013 Sep 11. No abstract available.
Results Reference
background
PubMed Identifier
27716201
Citation
Verbakel JY, Lemiengre MB, De Burghgraeve T, De Sutter A, Aertgeerts B, Shinkins B, Perera R, Mant D, Van den Bruel A, Buntinx F. Should all acutely ill children in primary care be tested with point-of-care CRP: a cluster randomised trial. BMC Med. 2016 Oct 6;14(1):131. doi: 10.1186/s12916-016-0679-2. Erratum In: BMC Med. 2017 May 2;15(1):93.
Results Reference
background
PubMed Identifier
34980633
Citation
Verbakel JYJ, De Burghgraeve T, Van den Bruel A, Coenen S, Anthierens S, Joly L, Laenen A, Luyten J, De Sutter A. Antibiotic prescribing rate after optimal near-patient C-reactive protein testing in acutely ill children presenting to ambulatory care (ARON project): protocol for a cluster-randomized pragmatic trial. BMJ Open. 2022 Jan 3;12(1):e058912. doi: 10.1136/bmjopen-2021-058912.
Results Reference
derived

Learn more about this trial

Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project

We'll reach out to this number within 24 hrs